Holen Sie sich die Stockscreener-App
1.885
4.14%
0.075
Handel nachbörslich:
1.90
0.015
+0.80%
Schlusskurs vom Vortag:
$1.81
Offen:
$1.86
24-Stunden-Volumen:
581.14K
Relative Volume:
0.56
Marktkapitalisierung:
$7.54M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-27.39M
KGV:
-1.1218
EPS:
-1.6803
Netto-Cashflow:
$-2.09M
1W Leistung:
-14.71%
1M Leistung:
-50.34%
6M Leistung:
-88.65%
1J Leistung:
+0.00%
1-Tages-Spanne:
$1.76
$1.95
1-Wochen-Bereich:
$1.71
$2.4464
52-Wochen-Spanne:
$1.6547
$84.00
Aspire Biopharma Holdings Inc Stock (ASBP) Company Profile
Firmenname
Aspire Biopharma Holdings Inc
Sektor
Branche
Telefon
561-704-8527
Adresse
23150 FASHION DRIVE, SUITE 232, ESTERO
Vergleichen Sie ASBP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ASBP
Aspire Biopharma Holdings Inc
|
1.885 | 7.24M | 0 | -27.39M | -2.09M | -1.6803 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.41 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
753.55 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
814.74 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
357.98 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.32 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Aspire Biopharma Holdings Inc Aktie (ASBP) Neueste Nachrichten
Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack) - citizen-times.com
Aspire Biopharma Announces Successful Pre-IND Meeting with FDA for High-Dose Sublingual Aspirin (OTASA) - hattiesburgamerican.com
Aspire BioPharma Welcomes Dr. Mark J. Jaroszeski as New Scientific Team Member - vcstar.com
Aspire Biopharma takes delivery of 2M units of BUZZ BOMB - TipRanks
Aspire Biopharma Scales Consumer Division with Delivery of Two Million BUZZ BOMB(TM) Units Featuring Modernized Brand Identity - ACCESS Newswire
Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation - gainesville.com
Aspire Biopharma launches brand redesign for BUZZ BOMB - TipRanks
Aspire Biopharma's Unveils Bold New Era for BUZZ BOMB(TM) Caffeine with Dynamic Website and Packaging Redesign - standard-journal.com
BUZZ BOMB caffeine gets sleek new look and direct-to-consumer website - Stock Titan
Aspire Biopharma files patent for first sublingual alprazolam powder By Investing.com - Investing.com Nigeria
Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Formulation of AlprazolamGeneric Xanax(R)for Rapid Anxiety Relief - columbiatribune.com
Aspire Biopharma files patent application for sublingual alprazolam formulation - TipRanks
Aspire Biopharma files patent for first sublingual alprazolam powder - Investing.com
New under-the-tongue Xanax powder aims to calm panic attacks in minutes - Stock Titan
Aspire Biopharma Announces Reverse Stock Split - azcentral.com
Aspire Biopharma Announces Resignation of Board Director - TipRanks
Aspire Biopharma Engages with Global Pharmaceutical Leaders at CPHI Frankfurt to Advance Partnership Discussions for its Sublingual High-Dose Aspirin - vcstar.com
Aspire Biopharma Holdings sets share limit for stock incentive plan and approves equity award agreements - Investing.com Nigeria
Aspire Biopharma Adopts Equity Plan Limits and Award Agreements - TipRanks
Aspire Biopharma announces 1-for-40 reverse stock split By Investing.com - Investing.com Nigeria
Aspire Biopharma announces 1-for-40 reverse stock split - Investing.com
International Business Times - FinancialContent
Aspire Biopharma names new executive chair - MSN
Aspire Biopharma director Surendra Ajjarapu resigns from board By Investing.com - Investing.com Canada
Aspire Biopharma director Surendra Ajjarapu resigns from board - Investing.com
Aspire Biopharma Approves Key Proposals at Special Meeting - MSN
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
ASBP Stock Soars 32% After Favorable Feedback From FDA For Its Aspirin – Retail Expects Licensing Negotiations Soon - Stocktwits
FDA feedback clears path for Aspire Biopharma’s heart attack drug By Investing.com - Investing.com Nigeria
Aspire Biopharma Holdings, Inc.Common Stock (NQ: ASBP - FinancialContent
ASBP stock soars 32% after favorable feedback from FDA for its aspirin – retail expects licensing negotiations soon - MSN
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Rockford Register Star: Local News, Politics & Sports in Rockford, IL - FinancialContent
Aspire Biopharma stock soars after FDA meeting clears path for heart attack drug - Investing.com Nigeria
Aspire Biopharma stock soars after FDA meeting clears path for heart attack drug By Investing.com - Investing.com South Africa
Finanzdaten der Aspire Biopharma Holdings Inc-Aktie (ASBP)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.92%
2.36%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):